NASDAQ
YMTX

Yumanity Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Yumanity Therapeutics Inc Stock Price

Vitals

Today's Low:
$1.4
Today's High:
$1.89
Open Price:
$1.63
52W Low:
$1.4
52W High:
$2.2194
Prev. Close:
$1.74
Volume:
0

Company Statistics

Market Cap.:
$20.52 million
Book Value:
0.504
Revenue TTM:
$4.84 million
Operating Margin TTM:
-563%
Gross Profit TTM:
$-18366000
Profit Margin:
0%
Return on Assets TTM:
-42.93%
Return on Equity TTM:
-168.66%

Company Profile

Yumanity Therapeutics Inc had its IPO on 2016-02-11 under the ticker symbol YMTX.

The company operates in the Healthcare sector and Biotechnology industry. Yumanity Therapeutics Inc has a staff strength of 40 employees.

Stock update

Shares of Yumanity Therapeutics Inc opened at $1.63 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.4 - $1.89, and closed at $1.89.

This is a +8.62% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Yumanity Therapeutics Inc have increased by +400%.

Yumanity Therapeutics Inc's Key Ratios

Yumanity Therapeutics Inc has a market cap of $20.52 million, indicating a price to book ratio of 3.3307 and a price to sales ratio of 3.9005.

In the last 12-months Yumanity Therapeutics Inc’s revenue was $4.84 million with a gross profit of $-18366000 and an EBITDA of $-27043000. The EBITDA ratio measures Yumanity Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Yumanity Therapeutics Inc’s operating margin was -563% while its return on assets stood at -42.93% with a return of equity of -168.66%.

In Q3, Yumanity Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 14.3%.

Yumanity Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-4.241 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Yumanity Therapeutics Inc’s profitability.

Yumanity Therapeutics Inc stock is trading at a EV to sales ratio of 2.0704 and a EV to EBITDA ratio of -0.3219. Its price to sales ratio in the trailing 12-months stood at 3.9005.

Yumanity Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$9.58 million
Total Liabilities
$4.10 million
Operating Cash Flow
$0
Capital Expenditure
$53000
Dividend Payout Ratio
0%

Yumanity Therapeutics Inc ended 2024 with $9.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.58 million while shareholder equity stood at $5.48 million.

Yumanity Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.10 million in other current liabilities, 11000.00 in common stock, $-208902000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.42 million and cash and short-term investments were $8.42 million. The company’s total short-term debt was $204,000 while long-term debt stood at $0.

Yumanity Therapeutics Inc’s total current assets stands at $9.08 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0.00 compared to accounts payable of $1.69 million and inventory worth $0.

In 2024, Yumanity Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $53000.

Comparatively, Yumanity Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.89
52-Week High
$2.2194
52-Week Low
$1.4
Analyst Target Price
$27.6667

Yumanity Therapeutics Inc stock is currently trading at $1.89 per share. It touched a 52-week high of $2.2194 and a 52-week low of $2.2194. Analysts tracking the stock have a 12-month average target price of $27.6667.

Its 50-day moving average was $1.67 and 200-day moving average was $1.55 The short ratio stood at 1.24 indicating a short percent outstanding of 0%.

Around 1961.7% of the company’s stock are held by insiders while 2257% are held by institutions.

Frequently Asked Questions About Yumanity Therapeutics Inc

The stock symbol (also called stock or share ticker) of Yumanity Therapeutics Inc is YMTX

The IPO of Yumanity Therapeutics Inc took place on 2016-02-11

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$22320.75
207.25
+0.94%
$28.23
-0.02
-0.07%
$72.14
-3.87
-5.09%
$29
-0.35
-1.19%
$0
0
+11.11%
$179.3
-5.45
-2.95%
$27.3
-0.13
-0.47%
$2.2
0.1
+4.76%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Address

40 Guest Street, Boston, MA, United States, 02135